iRhythm completes VitalConnect acquisition for $237.5 million cash, issues up to 423,334 shares

• iRhythm completed its acquisition of VitalConnect, adding wearable biosensors, mobile cardiac telemetry, and multi-vitals monitoring across ambulatory and inpatient settings.
• Purchase consideration included USD 237.5 million cash, up to 423,334 shares at closing, and USD 10 million of working-capital funding pre-close.
• Deal expected to expand iRhythm’s addressable market into hospital-to-home care, leveraging its health system relationships and integrated clinical services.
• Transaction expected to lift revenue growth beginning in 2027 while maintaining a 15% adjusted EBITDA margin target for 2027.
• Updated 2026 guidance including VitalConnect is planned for the third-quarter earnings call on Nov. 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iRhythm Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050905PRIMZONEFULLFEED9839527) on October 05, 2026, and is solely responsible for the information contained therein.